MCRB - חוב כולל להון Seres Therapeutics, Inc

Seres Therapeutics (MCRB) leads the field of microbiome therapy, expanding Vowst sales and collaborating with Nestle Health Science to treat colitis. The company's production facilities have been modernized, and the capsule filling automation is functioning stably. The market price reflected in this chart demonstrates a debt-to-equity ratio of 1.54, while geopolitical risks and sanctions could complicate raw material logistics and patent protection.

For Seres Therapeutics (MCRB), the total liabilities-to-equity ratio determines financial stability amid the commercialization of the drug Vowst. This metric is calculated as the sum of all borrowed funds divided by net assets. By analyzing the total debt-to-equity chart on GURU.Markets, an investor assesses the risk of excessive leverage. The stability of this indicator confirms a balance between marketing expenses and available liquidity. A low debt load guarantees the company's viability while developing new pipelines.